OBJECTIVE: To compare outcomes after intramuscular progesterone (IMP) or 8% Crinone vaginal gel for luteal support for day 3 cryopreserved embryo transfer (CET). DESIGN: Retrospective cohort study with multivariable analysis. SETTING: Academic medical center. PATIENT(S): All autologous and donor egg in vitro fertilization and intracytoplasmic sperm injection patients who had a day 3 CET from January 1, 2008, to April 30, 2011, with luteal support using 25-50 mg/d IMP or 8% Crinone twice daily, initiated 3 days before the CET. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Implantation rate, clinical pregnancy, and live birth rates per CET. RESULT(S): IMP (n = 440) and Crinone (n = 298) recipients were similar for all demographic characteristics and cycle parameters assessed. Although implantation rates did not differ significantly between the two groups (Crinone vs. IMP: 19.6% vs. 30.4%), women supplemented with Crinone had significantly lower rates of clinical pregnancy (36.9% vs. 51.1%) and live birth (24.4% vs. 39.1%) compared with those on IMP. CONCLUSION(S): We observed that day 3 CET cycles with 8% Crinone luteal support had a 44% and 49% lower odds of clinical pregnancy and live birth, respectively, compared with those with IMP support. Further studies are required to identify the optimal timing and dose of 8% Crinone vaginal gel for use in CET cycles.
OBJECTIVE: To compare outcomes after intramuscular progesterone (IMP) or 8% Crinone vaginal gel for luteal support for day 3 cryopreserved embryo transfer (CET). DESIGN: Retrospective cohort study with multivariable analysis. SETTING: Academic medical center. PATIENT(S): All autologous and donor egg in vitro fertilization and intracytoplasmic sperm injection patients who had a day 3 CET from January 1, 2008, to April 30, 2011, with luteal support using 25-50 mg/d IMP or 8% Crinone twice daily, initiated 3 days before the CET. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Implantation rate, clinical pregnancy, and live birth rates per CET. RESULT(S): IMP (n = 440) and Crinone (n = 298) recipients were similar for all demographic characteristics and cycle parameters assessed. Although implantation rates did not differ significantly between the two groups (Crinone vs. IMP: 19.6% vs. 30.4%), women supplemented with Crinone had significantly lower rates of clinical pregnancy (36.9% vs. 51.1%) and live birth (24.4% vs. 39.1%) compared with those on IMP. CONCLUSION(S): We observed that day 3 CET cycles with 8% Crinone luteal support had a 44% and 49% lower odds of clinical pregnancy and live birth, respectively, compared with those with IMP support. Further studies are required to identify the optimal timing and dose of 8% Crinone vaginal gel for use in CET cycles.
Authors: Paula C Brady; Daniel J Kaser; Elizabeth S Ginsburg; Rachel K Ashby; Stacey A Missmer; Katharine F Correia; Catherine Racowsky Journal: J Assist Reprod Genet Date: 2014-03-12 Impact factor: 3.412
Authors: Michelle van der Linden; Karen Buckingham; Cindy Farquhar; Jan A M Kremer; Mostafa Metwally Journal: Cochrane Database Syst Rev Date: 2015-07-07
Authors: Daniel J Kaser; Stacey A Missmer; Katharine F Correia; S Temel Ceyhan; Mark D Hornstein; Catherine Racowsky Journal: J Assist Reprod Genet Date: 2013-07-04 Impact factor: 3.412
Authors: Daniel B Shapiro; Jennifer A Pappadakis; Nancy M Ellsworth; Howard I Hait; Zsolt Peter Nagy Journal: Hum Reprod Date: 2014-05-20 Impact factor: 6.918